|
1
|
Comar KM and Sanyal AJ: Portal
hypertensive bleeding. Gastroenterol Clin North Am. 32:1079–1105.
2003. View Article : Google Scholar
|
|
2
|
Augustin S, González A and Genescà J:
Acute esophageal variceal bleeding: Current strategies and new
perspectives. World J Hepatol. 2:261–274. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kovalak M, Lake J, Mattek N, Eisen G,
Lieberman D and Zaman A: Endoscopic screening for varices in
cirrhotic patients: data from a national endoscopic database.
Gastrointest Endosc. 65:82–88. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Groszmann RJ, Garcia-Tsao G, Bosch J, et
al: Beta-blockers to prevent gastroesophageal varices in patients
with cirrhosis. The N Engl J Med. 353:2254–2261. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Merli M, Nicolini G, Angeloni S, et al:
Incidence and natural history of small esophageal varices in
cirrhotic patients. J Hepatol. 38:266–272. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
D’Amico G, Pagliaro L and Bosch J:
Pharmacological treatment of portal hypertension: an evidence-based
approach. Semin Liver Dis. 19:475–505. 1999.PubMed/NCBI
|
|
7
|
Bosch J and Garcia-Pagan JC: Prevention of
variceal rebleeding. Lancet. 361:952–954. 2003. View Article : Google Scholar
|
|
8
|
de Franchis R: Evolving consensus in
portal hypertension. Report of the Baveno IV consensus workshop on
methodology of diagnosis and therapy in portal hypertension. J
Hepatol. 43:167–176. 2005.
|
|
9
|
Lunderquist A and Vang J: Sclerosing
injection of esophageal varices through transhepatic selective
catheterization of the gastric coronary vein. A preliminary report.
Acta Radiol Diagn (Stockh). 15:546–550. 1974.
|
|
10
|
Benner KG, Keeffe EB, Keller FS and Rösch
J: Clinical outcome after percutaneous transhepatic obliteration of
esophageal varices. Gastroenterology. 85:146–153. 1983.PubMed/NCBI
|
|
11
|
Chikamori F, Kuniyoshi N, Shibuya S and
Takase Y: Correlation between endoscopic and angiographic findings
in patients with esophageal and isolated gastric varices. Dig Surg.
18:176–181. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
L’Hermine C, Chastanet P, Delemazure O,
Bonniere PL, Durieu JP and Paris JC: Percutaneous transhepatic
embolization of gastroesophageal varices: results in 400 patients.
AJR Am J Roentgenol. 152:755–760. 1989.PubMed/NCBI
|
|
13
|
Koconis KG, Singh H and Soares G: Partial
splenic embolization in the treatment of patients with portal
hypertension: a review of the english language literature. J Vasc
Interv Radiol. 18:463–481. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi Y, Wang Y, Shi M, et al: Clinical
study of combined interventional treatment of portal hypertension.
Chin J Ethnomed Ethnopharm. 11:63–65. 2010.(In Chinese).
|
|
15
|
Henderson NC and Iredale JP: Liver
fibrosis: cellular mechanisms of progression and resolution. Clin
Sci (Lond). 112:265–280. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang J, Leclercq I, Brymora JM, et al:
Kupffer cells mediate leptin-induced liver fibrosis.
Gastroenterology. 137:713–723. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pesce JT, Ramalingam TR, Mentink-Kane MM,
et al: Arginase-1-expressing macrophages suppress Th2
cytokine-driven inflammation and fibrosis. PLoS Pathog.
5:e10003712009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao B, Radaeva S and Park O: Liver natural
killer and natural killer T cells: immunobiology and emerging roles
in liver diseases. J Leukoc Biol. 86:513–528. 2009.PubMed/NCBI
|
|
19
|
Delhem N, Carpentier A, Morales O, et al:
Regulatory T-cells and hepatocellular carcinoma: implication of the
regulatory T lymphocytes in the control of the immune response.
Bull Cancer. 95:1219–1225. 2008.(In French).
|
|
20
|
Delhem N, Cottrez F, Carpentier A, et al:
Role of the regulatory T lymphocytes in hepatitis C fibrosis
progression. Bull Cancer. 95:1029–1038. 2008.(In French).
|
|
21
|
Moriyasu F, Nishida O, Ban N, et al:
Measurement of portal vascular resistance in patients with portal
hypertension. Gastroenterology. 90:710–717. 1986.PubMed/NCBI
|
|
22
|
Scott J, Dick R, Long RG and Sherlock S:
Percutaneous transhepatic obliteration of gastro-oesophageal
varices. Lancet. 2:53–55. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sangro B, Bilbao I, Herrero I, et al:
Partial splenic embolization for the treatment of hypersplenism in
cirrhosis. Hepatology. 18:309–314. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alwmark A, Bengmark S, Gullstrand P,
Joelsson B, Lunderquist A and Owman T: Evaluation of splenic
embolization in patients with portal hypertension and
hypersplenism. Ann Surg. 196:518–524. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moro E, Pais M, Benvegnu M, Ferrari M and
Bittolo Bon G: Decrease of insulin resistance after splenectomy in
a diabetic patient with liver cirrhosis and portal hypertension.
Physiopathologic evaluation. Minerva Gastroenterol Dietol.
40:213–218. 1994.(In Italian).
|
|
26
|
Pålsson B, Hallén M, Forsberg AM and
Alwmark A: Partial splenic embolization: long-term outcome.
Langenbecks Arch Surg. 387:421–426. 2003.PubMed/NCBI
|
|
27
|
Tajiri T, Onda M, Yoshida H, Mamada Y,
Taniai N and Kumazaki T: Long-term hematological and biochemical
effects of partial splenic embolization in hepatic cirrhosis.
Hepatogastroenterology. 49:1445–1448. 2002.PubMed/NCBI
|
|
28
|
Yamaguchi S, Kawanaka H, Yoshida D,
Maehara Y and Hashizume M: Splenic hemodynamics and decreased
endothelial nitric oxide synthase in the spleen of rats with liver
cirrhosis. Life Sci. 80:2036–2044. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hoefs JC, Wang FW, Lilien DL, Walker B and
Kanel G: A novel, simple method of functional spleen volume
calculation by liver-spleen scan. J Nucl Med. 40:1745–1755.
1999.PubMed/NCBI
|
|
30
|
Chadburn A: The spleen: anatomy and
anatomical function. Semin Hematol. 37(Suppl 1): S13–S21. 2000.
View Article : Google Scholar
|
|
31
|
Okamoto A, Fujio K, van Rooijen N, et al:
Splenic phagocytes promote responses to nucleosomes in (NZB × NZW)
F1 mice. J Immunol. 181:5264–5271. 2008.PubMed/NCBI
|
|
32
|
Sekiguchi T, Nagamine T, Takagi H and Mori
M: Autoimmune thrombocytopenia in response to splenectomy in
cirrhotic patients with accompanying hepatitis C. World J
Gastroenterol. 12:1205–1210. 2006.PubMed/NCBI
|
|
33
|
Li ZF, Zhang S, Lv GB, et al: Changes in
count and function of splenic lymphocytes from patients with portal
hypertension. World J Gastroenterol. 14:2377–2382. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Harrington LE, Hatton RD, Mangan PR, et
al: Interleukin 17-producing CD4+ effector T cells
develop via a lineage distinct from the T helper type 1 and 2
lineages. Nat Immunol. 6:1123–1132. 2005.PubMed/NCBI
|
|
35
|
Infante-Duarte C, Horton HF, Byrne MC and
Kamradt T: Microbial lipopeptides induce the production of IL-17 in
Th cells. J Immunol. 165:6107–6115. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Park H, Li Z, Yang XO, et al: A distinct
lineage of CD4 T cells regulates tissue inflammation by producing
interleukin 17. Nat Immunol. 6:1133–1141. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sun HQ, Zhang JY, Zhang H, Zou ZS, Wang FS
and Jia JH: Increased Th17 cells contribute to disease progression
in patients with HBV-associated liver cirrhosis. J Viral Hepat.
19:396–403. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lemmers A, Moreno C, Gustot T, et al: The
interleukin-17 pathway is involved in human alcoholic liver
disease. Hepatology. 49:646–657. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang L, Chen S and Xu K: IL-17 expression
is correlated with hepatitis B-related liver diseases and fibrosis.
Int J Mol Med. 27:385–392. 2011.PubMed/NCBI
|
|
40
|
Ye Y, Xie X, Yu J, et al: Involvement of
Th17 and Th1 effector responses in patients with Hepatitis B. J
Clin Immunol. 30:546–555. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li H, Zheng HW, Chen H, et al: Hepatitis B
virus particles preferably induce Kupffer cells to produce TGF-β1
over pro-inflammatory cytokines. Dig Liver Dis. 44:328–333.
2012.PubMed/NCBI
|
|
42
|
Bettelli E, Carrier Y, Gao W, et al:
Reciprocal developmental pathways for the generation of pathogenic
effector TH17 and regulatory T cells. Nature. 441:235–238. 2006.
View Article : Google Scholar
|
|
43
|
Mangan PR, Harrington LE, O’Quinn DB, et
al: Transforming growth factor-beta induces development of the
T(H)17 lineage. Nature. 441:231–234. 2006. View Article : Google Scholar
|
|
44
|
Veldhoen M, Hocking RJ, Atkins CJ,
Locksley RM and Stockinger B: TGFbeta in the context of an
inflammatory cytokine milieu supports de novo differentiation of
IL-17-producing T cells. Immunity. 24:179–189. 2006. View Article : Google Scholar
|
|
45
|
Niedbala W, Wei XQ, Cai B, et al: IL-35 is
a novel cytokine with therapeutic effects against collagen-induced
arthritis through the expansion of regulatory T cells and
suppression of Th17 cells. Eur J Immunol. 37:3021–3029. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Collison LW, Chaturvedi V, Henderson AL,
et al: IL-35-mediated induction of a potent regulatory T cell
population. Nat Immunol. 11:1093–1101. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yang J, Yang M, Htut TM, et al:
Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22
and RORgamma t. Eur J Immunol. 38:1204–1214. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fontenot JD, Gavin MA and Rudensky AY:
Foxp3 programs the development and function of
CD4+CD25+ regulatory T cells. Nat Immunol.
4:330–336. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hori S, Nomura T and Sakaguchi S: Control
of regulatory T cell development by the transcription factor Foxp3.
Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Khattri R, Cox T, Yasayko SA and Ramsdell
F: An essential role for Scurfin in CD4+CD25+
T regulatory cells. Nat Immunol. 4:337–342. 2003. View Article : Google Scholar : PubMed/NCBI
|
